文献速递脑血管病神经重症与神经感染

基线降压治疗对BP TARGET试验中卒中严重程度和结局的影响

Effect of Baseline Antihypertensive Treatments on Stroke Severity and Outcomes in the BP TARGET Trial.
PubMed 文献 · Stroke · 2022-03-24

该研究为BP TARGET试验的事后分析,纳入203例接受血管内治疗且有基线降压治疗数据的缺血性卒中患者。结果显示,基线使用非肾素-血管紧张素系统(RAS)抑制剂者基线NIHSS评分更高、24小时颅内出血风险更高,而使用RAS抑制剂者基线NIHSS评分更低。

要点

  • 非RAS抑制剂组基线NIHSS评分较参照组高3.28分(95%CI 1.33-5.22;P=0.001)。
  • RAS抑制剂组基线NIHSS评分较参照组低2.81分(95%CI -5.37至-0.25;P=0.031)。
  • 非RAS抑制剂组24小时颅内出血风险约为参照组的2.48倍(95%CI 1.12-5.47;P=0.025)。

核心结论

  • 基线降压治疗对卒中严重程度和结局的影响因其对RAS的作用方向而异。
  • 卒中前使用RAS抑制剂的患者较使用非RAS抑制剂者卒中严重程度更轻、24小时颅内出血更少,24小时NIHSS评分有改善趋势。

研究设计与样本

  • BP TARGET试验的事后分析,纳入有入院时降压治疗数据的高血压急性缺血性卒中患者,均接受血管内治疗。
  • 降压治疗分为RAS抑制剂(ACE抑制剂、血管紧张素2受体阻滞剂和β受体阻滞剂)与非RAS抑制剂(钙通道阻滞剂和利尿剂)。
  • 共纳入203例至少使用一种降压治疗的患者。

主要发现

  • 非RAS抑制剂组基线NIHSS评分较参照组高,校正平均差为3.28(95%CI 1.33-5.22;P=0.001)。
  • RAS抑制剂组基线NIHSS评分较参照组低,校正平均差为-2.81(95%CI -5.37至-0.25;P=0.031)。
  • 非RAS抑制剂组24小时颅内出血发生率显著更高,校正比值比为2.48(95%CI 1.12-5.47;P=0.025)。
  • RAS抑制剂使用与更高的影像学颅内出血风险无关。
  • 非RAS抑制剂组24小时NIHSS改善较非使用者少,校正平均差为2.83(95%CI -0.16至5.81;P=0.063),未达统计学显著。

关键数值与推荐

  • 基线NIHSS评分关联采用线性混合模型,校正治疗数量和中心。
  • 24小时NIHSS变化和颅内出血关联采用线性混合模型,校正基线NIHSS、治疗数量、中心、年龄和性别。
  • 良好结局关联校正年龄、性别、糖尿病和当前吸烟。
  • 基线RAS抑制剂或非抑制剂治疗与良好结局均无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute ischemic stroke (AIS) patients with a history of hypertension experience worse outcomes, which may be explained by a deleterious impact of the renin-angiotensin system (RAS) overactivation. We sought to investigate whether prestroke antihypertensive treatments (AHT) influenced baseline stroke severity and neurological outcomes, in patients with AIS successfully treated by endovascular therapy. METHODS: We performed a post hoc analysis of the BP TARGET trial (Blood Pressure Target in Acute Stroke to Reduce Hemorrhage After Endovascular Therapy) and included hypertensive patients with available data regarding AHT at admission, categorized as RAS inhibitors (ACE [angiotensin-converting enzyme] inhibitors, ARBs [angiotensin 2 receptor blockers], and β-blockers) and non-RAS inhibitors (calcium channel blockers and diuretics). Associations of each AHT with National Institutes of Health Stroke Scale (NIHSS) score at baseline were investigated in linear mixed model adjusted for the number of treatments and center. Associations of each AHT with 24-hour NIHSS change, intracranial hemorrhage were performed using linear mixed model adjusted for baseline NIHSS, the number of treatments, center, age, and sex and adjusted for age, sex, diabetes, and current smoking for favorable outcome. All analyses were performed on cases-available data regarding the low number of missing data. RESULTS: Overall, 203 patients with at least one AHT were included. Patients under non-RAS inhibitor treatments had a higher NIHSS score at baseline (adjusted mean difference=3.28 [95% CI, 1.33-5.22]; P=0.001). Conversely, patients under RAS inhibitor treatments had a lower baseline NIHSS score (adjusted mean difference=-2.81 [95% CI, -5.37 to -0.25]; P=0.031). Intracranial hemorrhage occurrence was significantly more frequent in patients under non-RAS inhibitor treatments (adjusted odds ratio of 2.48 [95% CI, 1.12-5.47]; P=0.025). Conversely, the use of RAS inhibitor treatments before AIS was not associated with higher odds of radiographic intracranial hemorrhage. Patients with non-RAS inhibitor treatments had less improvement of NIHSS at 24 hours compared with patients without (adjusted mean difference, 2.83 [95% CI, -0.16 to 5.81]; P=0.063). Baseline RAS inhibitor or noninhibitor treatments were not associated with favorable outcome. CONCLUSIONS: We showed an opposite effect of baseline AHT, based on their effect on the RAS. Patients treated with RAS inhibitor agents before AIS exhibited less severe AIS compared with patients under non-RAS inhibitor treatments, developed less intracranial hemorrhage at 24 hours and had a trend toward better NIHSS score at 24 hours. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03160677.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Maïer B, Gory B, Lapergue B, et al. Effect of Baseline Antihypertensive Treatments on Stroke Severity and Outcomes in the BP TARGET Trial. Stroke. 2022. PMID: 35321558. doi:10.1161/STROKEAHA.121.037548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。